Literature DB >> 8564139

Nasal contribution to exhaled nitric oxide at rest and during breathholding in humans.

B Kimberly1, B Nejadnik, G D Giraud, W E Holden.   

Abstract

We characterized the nasal contribution to exhaled nitric oxide (NO) at rest and during breathholding in humans. Exhaled NO was greater during nose breathing (141 +/- 17 nl/min/M2, mean +/- SEM) compared with mouth breathing (68 +/- 6 nl/min/M2, n = 8, p < 0.001). After voluntary closure of the soft palate (VCSP) to eliminate nasal NO, exhaled NO from the mouth decreased further (30 +/- 4 nl/min/M2, p < 0.001). Release of NO into nasal passages during VCSP (217 +/- 19 nl/min/M2) was greater than exhaled NO during nasal breathing (141 +/- 17 nl/min/m2, p < 0.001), suggesting that nasal NO is taken up by the respiratory tract. During mouth breathing or nose breathing, NO concentrations sampled with a bronchoscope were higher in the nasopharynx than at the epiglottis or in the trachea in five subjects. Increased peak exhaled NO after a breathhold (33 +/- 7 ppb) was reduced (10 +/- 4 ppb, p < 0.001) after balloon occlusion of the nasopharynx. NO concentration during breathholding increased to a greater extent in the nasopharynx than in the pharynx or trachea. We conclude that the majority of exhaled NO at rest and during a breathhold originates in the nasopharynx.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8564139     DOI: 10.1164/ajrccm.153.2.8564139

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

Review 1.  Nasal nitric oxide in man.

Authors:  J O Lundberg; E Weitzberg
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

Review 2.  Exhaled nitric oxide during exercise.

Authors:  A W Sheel; J Road; D C McKenzie
Journal:  Sports Med       Date:  1999-08       Impact factor: 11.136

3.  Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding.

Authors:  S A Kharitonov; P J Barnes
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

4.  Effect of measurement conditions on measured levels of peak exhaled nitric oxide.

Authors:  C A Byrnes; S Dinarevic; C A Busst; E A Shinebourne; A Bush
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

5.  Examination of the Staphylococcus aureus nitric oxide reductase (saNOR) reveals its contribution to modulating intracellular NO levels and cellular respiration.

Authors:  A M Lewis; S S Matzdorf; J L Endres; I H Windham; K W Bayles; K C Rice
Journal:  Mol Microbiol       Date:  2015-03-16       Impact factor: 3.501

6.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

Authors:  Dieter Worlitzsch; Robert Tarran; Martina Ulrich; Ute Schwab; Aynur Cekici; Keith C Meyer; Peter Birrer; Gabriel Bellon; Jürgen Berger; Tilo Weiss; Konrad Botzenhart; James R Yankaskas; Scott Randell; Richard C Boucher; Gerd Döring
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

7.  Correlation of nasal nitric oxide measurement with computed tomography findings in chronic rhinosinusitis.

Authors:  Yogesh G Dabholkar; Akanksha A Saberwal; Haritosh K Velankar; Adip K Shetty; Nilesh P Chordia; Sneha R Budhwani
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2013-11-20

Review 8.  Exhaled nitric oxide in the diagnosis and management of asthma: clinical implications.

Authors:  G W Rodway; J Choi; L A Hoffman; J M Sethi
Journal:  Chron Respir Dis       Date:  2009       Impact factor: 2.444

Review 9.  Partitioned exhaled nitric oxide to non-invasively assess asthma.

Authors:  James L Puckett; Steven C George
Journal:  Respir Physiol Neurobiol       Date:  2008-07-31       Impact factor: 1.931

10.  Bacterial nitric oxide detoxification prevents host cell S-nitrosothiol formation: a novel mechanism of bacterial pathogenesis.

Authors:  Jay R Laver; Tânia M Stevanin; Sarah L Messenger; Amy Dehn Lunn; Margaret E Lee; James W B Moir; Robert K Poole; Robert C Read
Journal:  FASEB J       Date:  2009-08-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.